- Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188
- Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability
- The company believes that it has maximized its intellectual property position around DMT
- N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$9.00 per share
Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188 (“N,N-dimethyltryptamine” or “DMT”).
A novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter.
CEO Chris Moreau sat down with Dave Jackson to discuss the news.
Many drug compounds’ core structures can be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability.
The company believes that it has maximized its intellectual property position around DMT, which includes filing patent applications for new novel salt forms, as well as dosing, formulation, and method of use patent applications for stroke rehabilitation.
Algernon recently announced that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application, with the United Kingdom Medicines and Healthcare Products Regulatory Agency for its planned Phase 1 DMT clinical human stroke study.
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug-producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$9.00 per share.
